{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T04:18:53Z","timestamp":1785039533490,"version":"3.55.0"},"reference-count":61,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,8]],"date-time":"2022-06-08T00:00:00Z","timestamp":1654646400000},"content-version":"vor","delay-in-days":554,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","exphem.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Hematology"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.exphem.2020.08.008","type":"journal-article","created":{"date-parts":[[2020,8,22]],"date-time":"2020-08-22T01:39:10Z","timestamp":1598060350000},"page":"11-18.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":61,"special_numbering":"C","title":["Efficacy and safety of recently approved drugs for sickle cell disease: a review of clinical trials"],"prefix":"10.1016","volume":"92","author":[{"given":"Muhammad Ashar","family":"Ali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6727-2591","authenticated-orcid":false,"given":"Asrar","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hafsa","family":"Chaudry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8306-8788","authenticated-orcid":false,"given":"Wajeeha","family":"Aiman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sobia","family":"Aamir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9471-735X","authenticated-orcid":false,"given":"Muhammad Yasir","family":"Anwar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anam","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.exphem.2020.08.008_bib0001","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1016\/S0140-6736(10)61029-X","article-title":"Sickle-cell disease","volume":"376","author":"Rees","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.exphem.2020.08.008_bib0002","series-title":"StatPearls","article-title":"Sickle cell disease","author":"Sedrak","year":"2020"},{"key":"10.1016\/j.exphem.2020.08.008_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2019.05.004","article-title":"Sickle cell disease: clinical presentation and management of a global health challenge","volume":"37","author":"Houwing","year":"2019","journal-title":"Blood Rev"},{"key":"10.1016\/j.exphem.2020.08.008_bib0004","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/0736-4679(88)90329-0","article-title":"Harwood-Nuss Al. Sickle-cell anemia\u2014a review","volume":"6","author":"Galloway","year":"1988","journal-title":"J Emerg Med"},{"issue":"Suppl 1","key":"10.1016\/j.exphem.2020.08.008_bib0005","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.2119\/molmed.2014.00187","article-title":"Advances in sickle cell therapies in the hydroxyurea era","volume":"20","author":"Field","year":"2014","journal-title":"Mol Med"},{"key":"10.1016\/j.exphem.2020.08.008_bib0006","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.3324\/haematol.2017.175646","article-title":"Hydroxyurea differentially modulates activator and repressors of \u03b3-globin gene in erythroblasts of responsive and non-responsive patients with sickle cell disease in correlation with Index of Hydroxyurea Responsiveness","volume":"102","author":"Zhu","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.exphem.2020.08.008_bib0007","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.hoc.2016.01.011","article-title":"Management of patients with sickle cell disease using transfusion therapy: guidelines and complications","volume":"30","author":"Chou","year":"2016","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.exphem.2020.08.008_bib0008","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1080\/17474086.2018.1486703","article-title":"Stem cell transplantation in sickle cell disease: therapeutic potential and challenges faced","volume":"11","author":"Leonard","year":"2018","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.exphem.2020.08.008_bib0009","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1002\/iub.584","article-title":"Role of oxidative stress in the pathogenesis of sickle cell disease","volume":"64","author":"Chirico","year":"2012","journal-title":"IUBMB Life"},{"key":"10.1016\/j.exphem.2020.08.008_bib0010","first-page":"131a","article-title":"Increased red cell glutamate in sickle cell disease: evidence that increased glutamine availability is a mechanism for increased total NAD","volume":"43","author":"Niihara","year":"1995","journal-title":"J Investig Med"},{"key":"10.1016\/j.exphem.2020.08.008_bib0011","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1111\/bcp.13896","article-title":"Pharmacokinetics and pharmacodynamics of voxelotor (GBT440) in healthy adults and patients with sickle cell disease","volume":"85","author":"Hutchaleelaha","year":"2019","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.exphem.2020.08.008_bib0012","article-title":"Advances in sickle cell disease treatments","author":"Pavan","year":"2020","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.exphem.2020.08.008_bib0013","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1182\/blood.V98.6.1955","article-title":"P-Selectin mediates the adhesion of sickle erythrocytes to the endothelium","volume":"98","author":"Matsui","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2020.08.008_bib0014","doi-asserted-by":"crossref","first-page":"3047","DOI":"10.1073\/pnas.052522799","article-title":"Primary role for adherent leukocytes in sickle cell vascular occlusion: a new paradigm","volume":"99","author":"Turhan","year":"2002","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.exphem.2020.08.008_bib0015","first-page":"24","article-title":"Two new drugs for sickle cell disease","volume":"120","author":"Aschenbrenner","year":"2020","journal-title":"Am J Nurs"},{"key":"10.1016\/j.exphem.2020.08.008_bib0016","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.exphem.2020.08.008_bib0017","doi-asserted-by":"crossref","first-page":"116","DOI":"10.4172\/2167-065X.1000116","article-title":"L-Glutamine therapy reduces hospitalization for sickle cell anemia and sickle \u03b2\u00b0-thalassemia patients at six months: a phase II randomized trial","volume":"3","author":"Niihara","year":"2014","journal-title":"Clin Pharmacol Biopharm"},{"key":"10.1016\/j.exphem.2020.08.008_bib0018","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1056\/NEJMoa1715971","article-title":"A phase 3 trial of L-glutamine in sickle cell disease","volume":"379","author":"Niihara","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2020.08.008_bib0019","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1182\/blood-2018-08-868893","article-title":"A phase 1\/2 ascending dose study and open-label extension study of voxelotor in patients with sickle cell disease","volume":"133","author":"Howard","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2020.08.008_bib0020","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1056\/NEJMoa1903212","article-title":"A phase 3 randomized trial of voxelotor in sickle cell disease","volume":"381","author":"Vichinsky","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2020.08.008_bib0021","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1056\/NEJMoa1611770","article-title":"Crizanlizumab for the prevention of pain crises in sickle cell disease","volume":"376","author":"Ataga","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2020.08.008_bib0022","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/ajh.25308","article-title":"Effect of crizanlizumab on pain crises in subgroups of patients with sickle cell disease: a SUSTAIN study analysis","volume":"94","author":"Kutlar","year":"2019","journal-title":"Am J Hematol"},{"key":"10.1016\/j.exphem.2020.08.008_bib0023","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1002\/(SICI)1096-8652(199806)58:2<117::AID-AJH5>3.0.CO;2-V","article-title":"Oral L\u2010glutamine therapy for sickle cell anemia: I. Subjective clinical improvement and favorable change in red cell NAD redox potential","volume":"58","author":"Niihara","year":"1998","journal-title":"Am J Hematol"},{"key":"10.1016\/j.exphem.2020.08.008_bib0024","unstructured":"A voxelotor for sickle cell anemia patients at highest risk for progression of chronic kidney disease. Available at: https:\/\/ClinicalTrials.gov\/show\/NCT04335721. Accessed January 8, 2020."},{"key":"10.1016\/j.exphem.2020.08.008_bib0025","unstructured":"Dose escalation study to evaluate the safety, tolerability, PK and PD of voxelotor in patients with SCD. Available at: https:\/\/ClinicalTrials.gov\/show\/NCT04247594. Accessed January 8, 2020."},{"key":"10.1016\/j.exphem.2020.08.008_bib0026","unstructured":"Study to evaluate the effect of GBT440 on TCD in pediatrics with sickle cell disease. Available at: https:\/\/ClinicalTrials.gov\/show\/NCT04218084. Accessed January 8, 2020."},{"key":"10.1016\/j.exphem.2020.08.008_bib0027","unstructured":"Pediatric open-label extension of voxelotor. Available at: https:\/\/ClinicalTrials.gov\/show\/NCT04188509. Accessed January 8, 2020."},{"key":"10.1016\/j.exphem.2020.08.008_bib0028","unstructured":"Study exploring the effect of crizanlizumab on kidney function in patients with chronic kidney disease caused by sickle cell disease. Available at: https:\/\/ClinicalTrials.gov\/show\/NCT04053764. Accessed January 8, 2020."},{"key":"10.1016\/j.exphem.2020.08.008_bib0029","unstructured":"A study to evaluate the safety and efficacy of crizanlizumab in sickle cell disease related priapism. Available at: https:\/\/ClinicalTrials.gov\/show\/NCT03938454. Accessed January 8, 2020."},{"key":"10.1016\/j.exphem.2020.08.008_bib0030","unstructured":"Study of two doses of crizanlizumab versus placebo in adolescent and adult sickle cell disease patients. Available at: https:\/\/ClinicalTrials.gov\/show\/NCT03814746. Accessed January 8, 2020."},{"key":"10.1016\/j.exphem.2020.08.008_bib0031","unstructured":"Study to assess the effect of long-term treatment with voxelotor in participants who have completed treatment in Study GBT440-031. Available at: https:\/\/ClinicalTrials.gov\/show\/NCT03573882. Accessed January 8, 2020."},{"key":"10.1016\/j.exphem.2020.08.008_bib0032","unstructured":"Study of dose confirmation and safety of crizanlizumab in pediatric sickle cell disease patients. Available at: https:\/\/ClinicalTrials.gov\/show\/NCT03474965. Accessed January 8, 2020."},{"key":"10.1016\/j.exphem.2020.08.008_bib0033","unstructured":"Pharmacokinetics and pharmacodynamics study of SEG101 (crizanlizumab) in sickle cell disease (SCD) patients with vaso-occlusive crisis (VOC). Available at: https:\/\/ClinicalTrials.gov\/show\/NCT03264989. Accessed January 8, 2020."},{"key":"10.1016\/j.exphem.2020.08.008_bib0034","unstructured":"Study to evaluate the effect of GBT440 in pediatrics with sickle cell disease. Available at: https:\/\/ClinicalTrials.gov\/show\/NCT02850406. Accessed January 8, 2020."},{"issue":"Suppl 1","key":"10.1016\/j.exphem.2020.08.008_bib0035","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1182\/bloodadvances.2019GS121552","article-title":"Capacity building of stem cell transplantation facilities in Pakistan: joint efforts of NIBD, government, and private-sector institutions","volume":"3","author":"Zaidi","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.exphem.2020.08.008_bib0036","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/j.bbmt.2008.06.005","article-title":"Paucity of HLA-identical unrelated donors for African-Americans with hematologic malignancies: the need for new donor options","volume":"14","author":"Dew","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.exphem.2020.08.008_bib0037","first-page":"366","article-title":"The cost of hematopoietic stem-cell transplantation in the United States","volume":"10","author":"Broder","year":"2017","journal-title":"Am Health Drug Benefits"},{"key":"10.1016\/j.exphem.2020.08.008_bib0038","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/ajh.24587","article-title":"Hydroxyurea effectiveness in children and adolescents with sickle cell anemia: a large retrospective, population-based cohort","volume":"92","author":"Quarmyne","year":"2017","journal-title":"Am J Hematol"},{"key":"10.1016\/j.exphem.2020.08.008_bib0039","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.hemonc.2018.01.001","article-title":"Beliefs about hydroxyurea in youth with sickle cell disease","volume":"11","author":"Badawy","year":"2018","journal-title":"Hematol Oncol Stem Cell Ther"},{"key":"10.1016\/j.exphem.2020.08.008_bib0040","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1001\/jama.289.13.1645","article-title":"Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment","volume":"289","author":"Steinberg","year":"2003","journal-title":"JAMA"},{"issue":"10 Suppl 1","key":"10.1016\/j.exphem.2020.08.008_bib0041","first-page":"405A","article-title":"Increased red cell glutamine availability in sickle cell anemia: I. Demonstration of a several fold increase in active glutamine transport in intact red cells","volume":"84","author":"Niihara","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2020.08.008_bib0042","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1182\/blood.V116.21.1636.1636","article-title":"Metabolic fate of oral glutamine supplementation within plasma and erythrocytes of patients with sickle cell disease: preliminary pharmacokinetics results","volume":"116","author":"Morris","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2020.08.008_bib0043","series-title":"Featured clinical topic: summary of the 2014 NHLBI guidelines to manage sickle cell disease","author":"Hsu","year":"2014"},{"key":"10.1016\/j.exphem.2020.08.008_bib0044","doi-asserted-by":"crossref","first-page":"3991","DOI":"10.1182\/blood-2007-08-110098","article-title":"Efficacy and safety of the Gardos channel blocker, senicapoc (ICA-17043), in patients with sickle cell anemia","volume":"111","author":"Ataga","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2020.08.008_bib0045","doi-asserted-by":"crossref","first-page":"18010","DOI":"10.1038\/nrdp.2018.10","article-title":"Sickle cell disease","volume":"4","author":"Kato","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.exphem.2020.08.008_bib0046","first-page":"288","article-title":"Cerebrovascular accidents in sickle cell disease: rates and risk factors","volume":"91","author":"Ohene-Frempong","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2020.08.008_bib0047","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S0140-6736(17)30193-9","article-title":"Sickle cell disease","volume":"390","author":"Ware","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.exphem.2020.08.008_bib0048","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/j.1365-2141.2010.08520.x","volume":"153","author":"Ataga","year":"2011","journal-title":"Br J Haematol"},{"key":"10.1016\/j.exphem.2020.08.008_bib0049","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1056\/NEJMoa1512021","article-title":"A multinational trial of prasugrel for sickle cell vaso-occlusive events","volume":"374","author":"Heeney","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2020.08.008_bib0050","unstructured":"Efficacy and safety of rivipansel (GMI-1070) in the treatment of vaso-occlusive crisis in hospitalized subjects with sickle cell disease. Available at: https:\/\/ClinicalTrials.gov\/show\/NCT02187003. Accessed January 8, 2020."},{"key":"10.1016\/j.exphem.2020.08.008_bib0051","unstructured":"Sevuparin infusion for the management of acute VOC in subjects with SCD. Available at: https:\/\/ClinicalTrials.gov\/show\/NCT02515838. Accessed January 8, 2020."},{"key":"10.1016\/j.exphem.2020.08.008_bib0052","series-title":"Healthcare Cost and Utilization Project (HCUP) Statistical Briefs","article-title":"Characteristics of inpatient hospital stays involving sickle cell disease, 2000\u20132016: Statistical Brief #251","author":"Fingar","year":"2019"},{"key":"10.1016\/j.exphem.2020.08.008_bib0053","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1016\/j.jval.2020.04.1615","article-title":"PCN125 novel anti-sickling agents and hydroxyurea versus chronic transfusions in sickle cell disease: a cost-effectiveness analysis","volume":"23","author":"Onasanya","year":"2020","journal-title":"Value Health"},{"key":"10.1016\/j.exphem.2020.08.008_bib0054","doi-asserted-by":"crossref","first-page":"e183","DOI":"10.1016\/S2352-3026(19)30031-6","article-title":"Effect of increased dose of total body irradiation on graft failure associated with HLA-haploidentical transplantation in patients with severe haemoglobinopathies: a prospective clinical trial","volume":"6","author":"Bola\u00f1os-Meade","year":"2019","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.exphem.2020.08.008_bib0055","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.bbmt.2017.08.039","article-title":"HLA haploidentical stem cell transplant with pretransplant immunosuppression for patients with sickle cell disease","volume":"24","author":"Pawlowska","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.exphem.2020.08.008_bib0056","unstructured":"A study evaluating gene therapy with BB305 lentiviral vector in sickle cell disease. Available at: https:\/\/ClinicalTrials.gov\/show\/NCT04293185. Accessed January 8, 2020."},{"key":"10.1016\/j.exphem.2020.08.008_bib0057","unstructured":"CSL200 gene therapy in adults with severe sickle cell disease. Available at: https:\/\/ClinicalTrials.gov\/show\/NCT04091737. Accessed January 8, 2020."},{"key":"10.1016\/j.exphem.2020.08.008_bib0058","unstructured":"Safety and efficacy of gene therapy of the sickle cell disease by transplantation of an autologous CD34+ enriched cell fraction that contains CD34+ cells transduced ex vivo with the GLOBE1 lentiviral vector expressing the \u03b2AS3 globin gene in patients with sickle cell disease (DREPAGLOBE). Available at: https:\/\/ClinicalTrials.gov\/show\/NCT03964792. Accessed January 8, 2020."},{"key":"10.1016\/j.exphem.2020.08.008_bib0059","unstructured":"Gene transfer for sickle cell disease. Available at: https:\/\/ClinicalTrials.gov\/show\/NCT03282656. Accessed January 8, 2020."},{"key":"10.1016\/j.exphem.2020.08.008_bib0060","unstructured":"Stem cell gene therapy for sickle cell disease. Available at: https:\/\/ClinicalTrials.gov\/show\/NCT02247843. Accessed January 8, 2020."},{"key":"10.1016\/j.exphem.2020.08.008_bib0061","unstructured":"Gene transfer for patients with sickle cell disease. Available at: https:\/\/ClinicalTrials.gov\/show\/NCT02186418. Accessed January 8, 2020."}],"container-title":["Experimental Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X20303568?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X20303568?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T08:35:19Z","timestamp":1759566919000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0301472X20303568"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":61,"alternative-id":["S0301472X20303568"],"URL":"https:\/\/doi.org\/10.1016\/j.exphem.2020.08.008","relation":{},"ISSN":["0301-472X"],"issn-type":[{"value":"0301-472X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of recently approved drugs for sickle cell disease: a review of clinical trials","name":"articletitle","label":"Article Title"},{"value":"Experimental Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.exphem.2020.08.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 ISEH -- Society for Hematology and Stem Cells. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}